|
WEDNESDAY, MARCH 26
7:00am Registration (Open until 5:30pm)
8:00 �E9:40 PLENARY KEYNOTE SESSION
Risk Diagnosis for Disease Prevention
C. Thomas Caskey, M.D., F.A.C.P., Director and Chief Executive Officer, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center
Disruption of the Pharmaceutical Industry: Moving from Products to Solutions
Theodore J. Torphy, Ph.D., Corporate Vice President & Head, Science & Technology, Johnson & Johnson
9:40 Grand Opening Refreshment Break in the Exhibit Hall
11:00 Chairperson's Opening Remarks
Keynote Presentation
11:10 Challenges for Discoveries and Translation for Stem Cell Research
 |
Alan O. Trounson, Ph.D., President, California Institute for Regenerative Medicine |
11:40 Selection of a Multi-Disciplinary Team
Jon Mogford, Ph.D., Program Manager, Defense Sciences Office, DARPA
12:10pmMultidisciplinary Team Development and Management in Complex Scientific Enterprises
Peter C. Johnson, M.D., President and CEO, Scintellix, LLC
Complex enterprises such as multidisciplinary scientific initiatives require deft construction and management. Skill needs must be defined to identify key participants. This must be combined with a more subtle assessment of needed personal attributes so that a balanced and cooperative team can emerge. The mission of the initiative will determine the type of culture needed in the ultimate organization. Leadership must continuously keep the mission in the minds of participants and fairly assess the degree to which contribution by and reward of participants is occurring. Since most such enterprises have a component of voluntary commitment, messaging regarding the overarching impact of the joint enterprise must be frequent and tied to the day-to-day activities of participants in a balanced way.
12:40 Technology Spotlight Sponsored by
BioMark Dynamic Arrays for Single-Cell Gene Expression Analysis
Ken Livak, Ph.D., Research and Development, Fluidigm Corporation
Variation in gene expression at the single-cell level may be a critical parameter in understanding the differentiation of stem cells; however, single-cell samples have been difficult and expensive to analyze. BioMarkT dynamic arrays provide a convenient and cost-effective method for performing multiple RNA expression assays on multiple single-cell samples.
1:10 Walk & Talk Luncheon in the Exhibit Hall
2:15 Chairperson's Remarks
2:20 Mesenchymal Cells for Skeletal Tissue Engineering
Michael T. Longaker, M.D., Deane P. and Louise Mitchell Professor, Director, Children's Surgical Research; Director, Program in Regenerative Medicine, Deputy Director, Institute of Stem Cell Biology and Regenerative Medicine, Lucile Packard Children's Hospital, Stanford University School of Medicine
Mesenchymal multipotent cells derived from bone marrow and adipose tissue are capable of osteogenic differentiation under the proper guidance and/or culture conditions. Recent advances in this area of research, both in vitro and in vivo, in animal models support the use of these cells for skeletal repair. This talk will review recent data in animal models and outline potential strategies for clinical application
2:50 Use of Mesenchymal Stem Cells in the Regulation of Inflammation: Examples for Future Therapies in the Lung
Mauricio Rojas, M.D., Assistant Professor, Division of Pulmonary, Allergy and Critical Care Medicine. Department of Medicine, Emory University
Bone marrow-derived mesenchymal stem cells (BMDMSCs) appear to be important in the regulation of acute inflammatory process. We are presenting examples of the use of BMDMSC in acute and chronic inflammatory diseases in the lung. We demonstrated that BMDMSC administration prevented endotoxin induced Acute Lung Injury (ALI), suppressing the endotoxin induced pro-inflammatory cytokines. To demonstrate the clinical relevance of these results, we are presenting new data that will show the association between the ability to induce mobilization of bone marrow derived cells and the survival of patients at the intensive care unit with ALI. Lung transplantation is a viable treatment option for end-stage pulmonary diseases, but development of obliterative bronchiolitis (OB), reduces survival, accounting for 30% of deaths after the third year. In this model, the systemic administration of BMDMSC prevents the development of OB. We were able to demonstrate the total inhibition of inflammation and fibrosis when the mice received a single dose of BMDMSC independent of the strain from where the cells were obtained.
3:20 Mesenchyamal Stem Cells for Vascular Regeneration
Song Li, Ph.D., Associate Professor, Bioengineering, University of California, Berkeley
A challenge in vascular tissue engineering is to establish expandable cell sources for the construction of tissue-engineered vascular grafts (TEVGs) that are non-thrombogenic and have long-term patency. Here we used TEVG as a model to demonstrate the potential of combining nanofibrous scaffolds and bone marrow mesenchymal stem cells (MSCs) for vascular tissue engineering. The results from artery bypass experiments showed that nanofibrous scaffolds allowed efficient infiltration of vascular cells and matrix remodeling. Furthermore, MSCs had anti-thrombogenic property and contributed to the long-term patency of vascular grafts. These results demonstrate the potential of combining stem cells and nanomaterials for tissue engineering and regenerative medicine.
3:50 Immunomodulatory Properties of Adult Stem Cells Used in Treatment of Graft vs Host Disease
Robert J. Deans, Ph.D., Senior Vice President, Regenerative Medicine, Athersys, Inc.
Adult stem cells can be a potent source of paracrine factors with significant clinical benefit. These include factors influencing inflammation, homing, angiogenesis and cytoprotection. We have developed an isolation system for an adherent bone marrow derived stem cell that possesses strong in vitro immunomodulatory properties, and shows significant benefit in Graft vs Host Disease animal models. The immunology and cell expansion properties of these pluripotent stem cells supports their use as a universal cell product, well suited as an adjunct cell therapy in allogeneic bone marrow transplant. Clinical history and business models for this category of adult stem cells in treatment of GVHD will be discussed.
4:20 Reception in the Exhibit Hall (Sponsorship Available)
5:00 Break-out Discussions in the Exhibit Hall
�E Commercialization of Cell Therapies
Host: Lee Buckler, LLB, Business Development, Progenitor Cell Therapy
�E Adult Stem Cells: Mechanism of Benefit and Emerging Technologies
Host: Robert J. Deans, Ph.D., Senior Vice President, Regenerative Medicine, Athersys, Inc.
�E The Federal Funding Scene
Host: Rosemarie Hunziker, Ph.D., Program Director, Tissue Engineering and Regenerative Medicine, NIBIB, NIH
�E Human Embryonic Stem Cells: Approaching a Set of Core Criteria
Host: Mark Levenstein, Ph.D., Scientist, WiCell Research Institute
6:00 End of Day
|
Japanese
Korean
English